Laura Brege

Laura Brege currently serves as a senior advisor to Second Genome. Ms. Brege also serves as senior advisor to BridgeBio Pharma (BBIO), a biotechnology company focused on creating medicines that target well-characterized genetic diseases. Previously, Ms. Brege was EVP and Chief Operating Officer of Onyx Pharmaceuticals (ONXX), an oncology biotechnology company acquired by Amgen, and Chief Financial Officer of COR Therapeutics (CORR), a biotechnology company specializing in cardiovascular disease, acquired by Millennium Pharmaceuticals. Earlier, Ms. Brege served as Chief Financial Officer of Flextronics, (FLEX) a global technology manufacturer, and as Treasurer of The Cooper Companies (COO).

Ms. Brege currently serves on the Board of Directors of several public life science companies, including Acadia Pharmaceuticals (ACAD), Pacira Pharmaceuticals (PCRX) and Mirum Pharmaceuticals (MIRM). She is also Chair of the international non-profit educational organization, CIEE. Ms. Brege earned a B.A. from Ohio University and an M.B.A. from the University of Chicago.